Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice

Rischio and Prevenzione Investigators

Abstract

Background: The optimization of preventive strategies in patients at high risk of cardiovascular events and the evaluation of bottlenecks and limitations of transferring current guidelines to the real world of clinical practice are important limiting steps to cardiovascular prevention. Treatment with n-3 polyunsaturated fatty acids improves prognosis after myocardial infarction, but evidence of this benefit is lacking in patients at high cardiovascular risk, but without a history of myocardial infarction.

Methods/design: Patients were eligible if their general practitioner (GP) considered them at high cardiovascular risk because of a cardiovascular disease other than myocardial infarction, or multiple risk factors (at least four major risk factors in non-diabetic patients and one in diabetics).Patients were randomly allocated to treatment with n-3 polyunsaturated fatty acids (1 g daily) or placebo in a double-blind study and followed up for five years by their GPs to assess the efficacy of the treatment in preventing cardiovascular mortality (including sudden death) and hospitalization for cardiovascular reasons. The secondary, epidemiological, aim of the study is to assess whether it is feasible to adopt current guidelines in everyday clinical practice, with a view to optimizing all the available preventive strategies in people at high cardiovascular risk.A nation-wide network of 860 GPs admitted 12,513 patients to the study between February 2004 and March 2007. The mean age was 64 years and 62% were males. Diabetes mellitus plus one or more cardiovascular risk factors was the main inclusion criterion (47%). About 30% of patients were included because of a history of atherosclerotic cardiovascular disease, 21% for four or more risk factors, and less than 1% for other reasons.

Discussion: The Rischio and Prevenzione (R&P) project provides a feasible model to test the efficacy of n-3 polyunsaturated fatty acid therapy in patients at high cardiovascular risk with no history of myocardial infarction, and to assess how to implement recommended preventive strategies in general practice.

Trial registration: ClinicalTrials.gov NCT00317707.

Figures

Figure 1
Figure 1
Rischio & Prevenzione study design. n-3PUFA indicate polyunsaturated fatty acids.
Figure 2
Figure 2
Rischio & Prevenzione research network. Red circle = Local health units in the Italian regions participating in the study. The nation-wide research network comprised 860 general practitioners in 57 local health units, who admitted 12,513 patients to the study.

References

    1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231–1248.
    1. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999;353:1547–1557. doi: 10.1016/S0140-6736(99)04021-0.
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757. doi: 10.1016/S0140-6736(06)68770-9.
    1. Leal J, Leungo-Fernandez R, Gray A, Peterson S, Rayner M. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart J. 2006;27:1610–1619. doi: 10.1093/eurheartj/ehi733.
    1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–1610. doi: 10.1016/S0195-668X(03)00347-6.
    1. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ Clinical research ed. 1998;316:1430–1434.
    1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II and III surveys in eight European countries. Lancet. 2009;373:929–940. doi: 10.1016/S0140-6736(09)60330-5.
    1. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Inter Med. 2001;161:1621–1628. doi: 10.1001/archinte.161.13.1621.
    1. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Family Practice. 2002;19:596–604. doi: 10.1093/fampra/19.6.596.
    1. Roccatagliata D, Avanzini F, Monesi L, Caimi V, Lauri D, Longoni P, Marchioli R, Tombesi M, Tognoni G, Roncaglioni MC. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management. 2006;2:507–514. doi: 10.2147/vhrm.2006.2.4.507. questa nostra referenza potremmo lasciarla qui.
    1. Monesi L, Avanzini F, Barlera S, Caimi V, Lauri D, Longoni P, Roccatagliata D, Tombesi M, Tognoni G, Roncaglioni MC. Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk? Eur J Clin Pharmacol. 2005;61:595–601. doi: 10.1007/s00228-005-0948-z. questa nostra referenza potremmo lasciarla qui.
    1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. doi: 10.1001/jama.295.2.180.
    1. Thomas P. The research needs of primary care. Trials must be relevant to patients. BMJ. 2000;321:2–3. doi: 10.1136/bmj.321.7252.2.
    1. De Maeseneer JM, van Driel ML, Green LA, van Weel C. The need for research in primary care. Lancet. 2003;362:1314–1319. doi: 10.1016/S0140-6736(03)14576-X.
    1. Is primary-care research a lost cause? Lancet. 2003;361:977. doi: 10.1016/S0140-6736(03)12837-1.
    1. Collaborative Group of the Primary Prevention Project (PPP) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89–95. doi: 10.1016/S0140-6736(00)03539-X.
    1. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–455. doi: 10.1016/S0140-6736(99)07072-5.
    1. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–1903. doi: 10.1161/01.CIR.0000014682.14181.F2.
    1. Roncaglioni MC, Avanzini F, Roccatagliata D, Monesi L, Tamayo-Benitez D, Tombesi M, Caimi V, Longoni P, Lauri D, Barlera S, Tognoni G. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil. 2004;11:233–238. doi: 10.1097/01.hjr.0000129737.84851.99.
    1. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. New Engl J Med. 1985;312:1205–1209.
    1. Fish consumption and mortality from coronary heart disease. New Engl J Med. 1985;313:820–824.
    1. Dolecek TA, Granditis G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT) World Review of Nutrition and Dietetics. 1991;66:205–216.
    1. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. New Engl J Med. 1997;336:1046–1053. doi: 10.1056/NEJM199704103361502.
    1. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. Jama. 2002;287:1815–1821. doi: 10.1001/jama.287.14.1815.
    1. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Jama. 1995;274:1363–1367. doi: 10.1001/jama.274.17.1363.
    1. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. Jama. 1998;279:23–28. doi: 10.1001/jama.279.1.23.
    1. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation. 2003;107:1372–1377. doi: 10.1161/01.CIR.0000055315.79177.16.
    1. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. New Engl J Med. 2002;346:1113–1118. doi: 10.1056/NEJMoa012918.
    1. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet. 1989;2:757–761. doi: 10.1016/S0140-6736(89)90828-3.
    1. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:9886–9890. doi: 10.1073/pnas.91.21.9886.
    1. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J. 1992;123:1555–1561. doi: 10.1016/0002-8703(92)90809-A.
    1. Christensen JH, Gustenhoff P, Ejlerseu E, Jessen T, Korup E, Rasmussen K, Dyerberg J, Schmidt EB. Fatty Acids And Ventricular Extrasystoles In Patients With Ventricular Tachyarrhythmias. Nutrition Research. 1995;15:1–8. doi: 10.1016/0271-5317(95)91647-U.
    1. Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J. 2001;3(Suppl):D98–D105.
    1. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757. doi: 10.1161/01.CIR.0000038493.65177.94.
    1. Avanzini F, Alli C, Bettelli G, Colombo F, Conforti L, Pirone F, Spagnoli A, Taioli E, Tognoni G, Villella M. Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. BMJ Clinical research ed. 1987;294:157–160. doi: 10.1136/bmj.294.6565.157.
    1. Cox DR. Regression Models and Life Tables (with Discussion) Journal of the Royal Statistical Society. 1972;34:187–220.
    1. Kalbfeisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons Inc; 1980.
    1. Geller NL, Pocock SJ. Interim Analysis in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. Biometrics. 1987;43:213–223. doi: 10.2307/2531962.
    1. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230. doi: 10.1016/S0140-6736(08)61239-8.
    1. Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. JACC. 2008;52:988–996.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner